Novartis Q1 sales, profit miss analyst expectations amid Covid-19 impact
Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%27-04-2021
27-04-2021
Novartis India Ltd - 500672 - Compliance Certificate Obtained By Novartis India Limited ('The Company') From A Practising Company Secretary For The Half Year Ended On March 31, 2021, In Terms Of The Provisions Of Regulations 40(9) & (10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
Please note that in terms of the SEBI Listing Regulations, the Company has obtained a Compliance Certificate from Saraf & Associates, Company Secretaries, for the half year ended on March 31, 2021 and the same is being submitted herewith. This is for your information and record. Thanking you.26-04-2021
NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Of Novartis India Limited ('The Company') Under Regulation 7(3) Read With Regulation 7(2) Of The Securities And Exchange Board Of India (LODR) Regulations, 2015 ('SEBI Listing Regulation')
Dear Sir/ Madam, We hereby confirm that during the half year ended on March 31, 2021, all the activities in relation to the facility of transferring the Equity Shares of the Company, both in physical and electronic form, were duly maintained by the Registrar and Share Transfer Agent of the Company viz. Link Intime India Private Limited, registered in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000004058 and having its registered Office at C - 101, 247 Park, L. B. S. Marg, Vikroli West, Mumbai - 400083.22-04-2021
NOVARTIS INDIA LTD. - 500672 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayNOVARTIS INDIA LTD. 2CINL24200MH1947PLC006104 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Trivikram Guda Designation: Company Secretary Compliance Officer EmailId: trivikram.guda@novartis.com Name of the Chief Financial Officer: Felix Doss Designation: Chief Financial Officer EmailId: felix.doss@novartis.com Date: 22/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.22-04-2021
Novartis India Ltd - 500672 - Shareholding for the Period Ended March 31, 2021
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here21-04-2021
Novartis India Ltd - 500672 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Trivikram GudaDesignation :- Company Secretary and Compliance Officer21-04-2021
Novartis agrees to make ingredients Roche's Actemra for COVID-19 patients
The arrangement is the third transaction signed by Novartis following agreements with BioNTech and CureVac to make therapies for other firms to help fight the pandemic.15-04-2021
NOVARTIS INDIA LTD. - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In reference to the above captioned subject, the certificate dated April 5, 2021, issued by the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited, in terms of the provisions of the said Regulations, for the quarter ended March 31, 2021, is enclosed herewith for your records as Annexure 1. This is for your information and record.07-04-2021
Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Newspaper advertisement by the Company regarding the Meeting of the Board of Directors of the Company for the fourth quarter and year ended March 31, 2021, in 'Financial Express' and 'Navshakti' on April 1, 2021. Enclosed herewith the copies of the newspaper. This is for your information and record.01-04-2021
Novartis India Ltd - 500672 - Board to consider FY21 results & Final Dividend on May 20, 2021
Novartis India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held onMay 20, 2021, inter alia, to consider the Audited financial results of the Company for the fourth quarter and financial year ending on March 31, 2021 ("said results") and recommendation of final dividend on Equity Share, if any, for the said year.In this connection, further note that pursuant to the Company's Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from April 01, 2021 to May 22, 2021 (both days inclusive).31-03-2021